Novel pMDI formulations for pulmonary delivery of proteins

被引:40
|
作者
Li, Hao-Ying [1 ]
Seville, Peter C. [1 ]
机构
[1] Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England
基金
英国工程与自然科学研究理事会;
关键词
Sodium carboxymethylcellulose; HFA-134a; pMDI; Protein; Spray-drying; SPRAY-DRIED POWDERS; AEROSOLISATION PROPERTIES; STABILITY; TETRAFLUOROETHANE; PERFORMANCE; PARTICLES; CELLULOSE; POLYMERS; AEROSOLS; RELEASE;
D O I
10.1016/j.ijpharm.2009.10.032
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In this paper, we demonstrate that co-spray-drying a model protein with sodium carboxymethylcellulose (NaCMC) protects protein integrity during spray-drying, and that the resultant spray-dried powders can be successfully dispersed in hydrofluoroalkane (HFA) propellant to prepare pressurised metered dose (pMDI) formulations that exhibit high respirable fractions. The spray-dried powders were formulated as HFA-134a pMDI suspensions in the absence of any other excipients (e.g. surfactants) or co-solvents (e.g ethanol). The in vitro aerosolisation profile of these systems was assessed using the twin stage impinger, fine particle fractions (FPF) >= 50% of the recovered dose were obtained. Following storage for five months, the aerosolisation performance was reassessed; the NaCMC-free formulation demonstrated a significant decrease in FPF, whereas the performance of the NaCMC-modified formulations was statistically equivalent to their initial performance. Thus, formulation of pMDI suspensions using NaCMC-based spray-dried powders is a promising approach for the pulmonary delivery of proteins and peptides. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:73 / 78
页数:6
相关论文
共 50 条
  • [41] Pulmonary Delivery of Proteins Using Nanocomposite Microcarriers
    Alfagih, Iman
    Kunda, Nitesh
    Alanazi, Fares
    Dennison, Sarah R.
    Somavarapu, Satyanarayana
    Hutcheon, Gillian A.
    Saleem, Imran Y.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 104 (12) : 4386 - 4398
  • [42] Dry powders for pulmonary delivery of peptides and proteins
    Okamoto, Hirokazu
    Todo, Hiroaki
    Iida, Kotaro
    Danjo, Kazumi
    KONA Powder and Particle Journal, 2002, 20 (March) : 71 - 83
  • [43] Modeling and Understanding Combination pMDI Formulations with Both Dissolved and Suspended Drugs
    Stein, Stephen W.
    Sheth, Poonam
    Younis, Usir S.
    Mogalian, Erik
    Myrdal, Paul B.
    MOLECULAR PHARMACEUTICS, 2015, 12 (09) : 3455 - 3467
  • [44] Extended release formulations using silk proteins for controlled delivery of therapeutics
    Yavuz, Burcin
    Chambre, Laura
    Kaplan, David L.
    EXPERT OPINION ON DRUG DELIVERY, 2019, 16 (07) : 741 - 756
  • [45] Novel delivery systems for coagulation proteins
    Miekka, SI
    Jameson, T
    Singh, M
    Woolverton, C
    Lin, HM
    Krajcik, R
    MacPhee, M
    Drohan, WN
    HAEMOPHILIA, 1998, 4 (04) : 436 - 442
  • [46] Chitosan-modified dry powder formulations for pulmonary gene delivery
    Li, Hao-Ying
    Birchall, James
    PHARMACEUTICAL RESEARCH, 2006, 23 (05) : 941 - 950
  • [47] Puerarin dry powder inhaler formulations for pulmonary delivery: Development and characterization
    Rashid, Md Abdur
    Muneer, Saiqa
    Wang, Tony
    Alhamhoom, Yahya
    Rintoul, Llew
    Izake, Emad L.
    Islam, Nazrul
    PLOS ONE, 2021, 16 (04):
  • [48] Chitosan-Modified Dry Powder Formulations for Pulmonary Gene Delivery
    Hao-Ying Li
    James Birchall
    Pharmaceutical Research, 2006, 23 : 941 - 950
  • [49] Nano-Formulations for Pulmonary Delivery: Past, Present, and Future Perspectives
    Peng, Siyuan
    Wang, Wenhao
    Zhang, Rui
    Wu, Chuanbin
    Pan, Xin
    Huang, Zhengwei
    PHARMACEUTICS, 2024, 16 (02)
  • [50] Novel nanoparticles for pulmonary gene delivery
    Bains, B. K.
    Taylor, G.
    Toon, R.
    Birchall, J.
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2007, 59 : A31 - A32